Rheumatology

IGBA Launches Global Biosimilars Week

November 16th 2020

By Tony Hagen

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

High Adherence Noted Among Infliximab Biosimilar Users

November 16th 2020

By Tony Hagen

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.

US Rheumatologists Understand and Accept Biosimilars, but Some Hesitation Remains

November 13th 2020

By Deana Ferreri, PhD

Samsung Launches Clinical Study of Denosumab Candidate

November 10th 2020

By Tony Hagen

The company is targeting the lucrative osteoporosis market dominated by Prolia, an Amgen product.

Multibiomarker Test Reads Out Positive in 2 Pfizer-Sponsored Studies

November 9th 2020

By Tony Hagen

A multibiomarker disease activity score looks at serum protein activity for a more sensitive evaluation of biosimilarity, investigators said at the American College of Rheumatology Convergence 2020 meeting.

ACR Abstract Roundup: Pfizer and Celltrion Agents Demonstrate Safety, Efficacy

November 7th 2020

By Tony Hagen

Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions.

Celltrion's CT-P17 Adalimumab Biosimilar Candidate Demonstrates Equivalence

November 6th 2020

By Tony Hagen

Separate studies including one on application methods for CT-P17 were reported at the American College of Rheumatology Convergence 2020 meeting.

Teva Cites Biosimilar Strength in Third-Quarter Earnings

November 5th 2020

By Tony Hagen

Launched in the US market in late 2019, Truxima (rituximab) has become a significant revenue driver for Teva.

Award: Samsung Bioepis Is Recognized for Advancing Biosimilars

November 5th 2020

By Tony Hagen

The company has multiple biosimilar products on the worldwide market and in development; in 2019, it gained World Health Organization precertification for a trastuzumab biosimilar (Ontruzant).

Expert Cautions on What to Expect From Real-World Biosimilar Evidence

November 4th 2020

By Tony Hagen

Expecting real-world evidence to confirm safety and efficacy of biosimilars is asking too much, Uwe Gudat, a pharmacovigilance expert from Fresenius Kabi, said at the Terrapinn Festival of Biologics Basel 2020.